In the past week, SRPT stock has gone down by -21.59%, with a monthly decline of -26.85% and a quarterly plunge of -36.56%. The volatility ratio for the week is 3.86%, and the volatility levels for the last 30 days are 4.01% for Sarepta Therapeutics Inc The simple moving average for the last 20 days is -22.86% for SRPT stock, with a simple moving average of -37.18% for the last 200 days.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
The price-to-earnings ratio for Sarepta Therapeutics Inc (NASDAQ: SRPT) is 33.13x, which is above its average ratio. Moreover, the 36-month beta value for SRPT is 0.75. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 9 as “overweight,” 1 as “hold,” and 1 as “sell.”
The public float for SRPT is 91.15M and currently, short sellers hold a 5.56% of that float. On March 18, 2025, SRPT’s average trading volume was 884.68K shares.
SRPT) stock’s latest price update
Sarepta Therapeutics Inc (NASDAQ: SRPT) has seen a decline in its stock price by -22.09 in relation to its previous close of 101.35. However, the company has experienced a -21.59% decline in its stock price over the last five trading sessions. proactiveinvestors.com reported 2025-03-18 that Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has died following treatment with its gene therapy ELEVIDYS. Although acute liver injury is a known potential side effect of ELEVIDYS and similar therapies, this level of severity had not been previously reported, the company said in a statement.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with Deutsche Bank repeating the rating for SRPT by listing it as a “Hold.” The predicted price for SRPT in the upcoming period, according to Deutsche Bank is $136 based on the research report published on February 11, 2025 of the current year 2025.
Needham, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $202, previously predicting the price at $205. The rating they have provided for SRPT stocks is “Buy” according to the report published on November 27th, 2024.
H.C. Wainwright gave a rating of “Sell” to SRPT, setting the target price at $80 in the report published on November 25th of the previous year.
SRPT Trading at -28.75% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.42% of loss for the given period.
Volatility was left at 4.01%, however, over the last 30 days, the volatility rate increased by 3.86%, as shares sank -26.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.45% lower at present.
During the last 5 trading sessions, SRPT fell by -22.93%, which changed the moving average for the period of 200-days by -33.23% in comparison to the 20-day moving average, which settled at $102.30. In addition, Sarepta Therapeutics Inc saw -35.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Nicaise Claude, who sale 2,491 shares at the price of $99.64 back on Mar 12 ’25. After this action, Nicaise Claude now owns 27,812 shares of Sarepta Therapeutics Inc, valued at $248,203 using the latest closing price.
Nicaise Claude, the Director of Sarepta Therapeutics Inc, proposed sale 2,491 shares at $99.65 during a trade that took place back on Mar 12 ’25, which means that Nicaise Claude is holding shares at $248,226 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.83 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 19.71, with 6.51 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.15. The debt to equity ratio resting at 0.87. The interest coverage ratio of the stock is 11.86.
Currently, EBITDA for the company is 316.89 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 4.14. The receivables turnover for the company is 2.93for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.20.
Conclusion
To wrap up, the performance of Sarepta Therapeutics Inc (SRPT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
